Anthem Biosciences Quarterly Results for Trading Insights

In Sept 2025, Anthem Biosciences (ANTHEM) reported revenue ₹598 Cr and net profit ₹173 Cr — revenue +8.1% YoY. For annual financials, live price and key ratios, visit ANTHEM share price.

Latest Quarter Net Profit
₹173 Cr
QSept 2025
Quarterly Results

ANTHEM Quarterly Results — Revenue, Profit & EPS Highlights

Anthem Biosciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with ANTHEM intrinsic value calculation to assess whether the stock is under or overvalued.

  • Revenue of ₹598 Cr in Sept 2025 (+20.3% vs Mar 2025, +8.1% vs Sept 2024)
  • Net Profit of ₹173 Cr in Sept 2025 (+108.4% vs Mar 2025, +6.8% vs Sept 2024)
  • EBITDA of ₹266 Cr in Sept 2025 (+27.3% vs Mar 2025)
  • Operating Margin of 40.0% in Sept 2025 (+0.0pp vs Mar 2025)
  • Earnings Per Share of ₹3.09 in Sept 2025 (+108.8% vs Mar 2025)

Anthem Biosciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS

ANTHEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 598 497 563 457 553 20.3% 8.1%
Net Profit (₹ Cr) 173 83 136 93 162 - -
EBITDA (₹ Cr) 266 209 214 165 223 - -
EPS (₹) 3.09 1.48 2.43 1.65 2.90 - -
Operating Margin (%) 40.0% 40.0% 35.0% 31.0% 37.0% - -

ANTHEM Share Price Trend — 1-Year Movement Across Quarterly Results

Anthem Biosciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse ANTHEM ownership pattern to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 28.9%
EBITDA Margin 44.5%
Operating Margin 40.0%
ROE (Annual) 28.7%

Balance Sheet Highlights

Total Assets ₹2,808 Cr
Total Equity ₹2,410 Cr
Current Assets ₹1,737 Cr
Current Liabilities ₹72 Cr

Cash Flow Analysis

Operating Cash Flow ₹418 Cr
Investing Cash Flow ₹-152 Cr
Financing Cash Flow ₹-134 Cr
Net Cash Flow ₹133 Cr

Current Market Data

Current Price ₹774.30
Exchange NSE
Last Updated Apr 28, 2026

Revenue Trend (₹ Cr)

Dec 2025 457
Jun 2025 563
Mar 2025 497
Sept 2025 598

Net Profit Trend (₹ Cr)

Dec 2025 93
Jun 2025 136
Mar 2025 83
Sept 2025 173

Operating Margin Trend (%)

Dec 2025 31.0%
Jun 2025 35.0%
Mar 2025 40.0%
Sept 2025 40.0%

ANTHEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Anthem Biosciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹415,924.72 Cr 1747.3 14,875 3,125 +10.8% - 21.0% 134.4
Divis Laboratories
Sept 2025 		₹171,625.44 Cr 6432.5 2,860 689 +7.1% - 24.1% 247.7
Torrent Pharmaceuti…
Sept 2025 		₹139,344.76 Cr 4182.9 3,219 591 +11.3% - 18.4% 238.5
Dr Reddys Laborator…
Sept 2025 		₹109,930.83 Cr 1354.6 9,135 1,337 +1.1% - 14.6% 83.7
Lupin
Sept 2025 		₹104,941.69 Cr 2302.7 6,921 1,485 +23.2% - 21.5% 71.2
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores